Urine 11-Dehydro-Thromboxane B2 in Aspirin-Naive Males with Metabolic Syndrome

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 Jun 24

PMID 35743540

Authors

Wieslaw Piechota

Pawel Krzesinski

Katarzyna Piotrowicz

Grzegorz Gielerak

Malgorzata Kurpaska

Alicja Raczka

Agnieszka Wozniak-Kosek

Affiliations

Soon will be listed here.

Abstract

Urine 11-dehydro-thromboxane B2 (11-dehydro-TXB2), an indirect measure of platelet activity, is elevated in cardiovascular diseases and diabetes. The purpose of our study was to determine whether urine 11-dehydro-TXB2 is elevated in aspirin-naive males with metabolic syndrome (MS) and to determine predictors of 11-dehydro-TXB2 levels. The secondary aim was to evaluate whether these MS patients could be potential candidates for the aspirin-mediated prevention of atherosclerotic cardiovascular diseases (ASCVDs). In 82 males with MS (76 hypertensive), anthropometric measures, urine 11-dehydro-TXB2, platelet count, creatinine, glucose, insulin, estimated insulin resistance, lipid parameters, high-sensitivity C-reactive protein (hs-CRP), adiponectin, homocysteine, and ten-year risk of fatal cardiovascular disease (SCORE) were assessed. Urine 11-dehydro-TXB2 levels were elevated (≥2500 pg/mg creatinine) in two-thirds of patients, including 11 high-risk patients (SCORE ≥ 5%). Homocysteine, adiponectin, hs-CRP, waist-to-hip ratio, and total cholesterol were found to be predictors of urine 11-dehydro-TXB2. In conclusion, there is a high incidence of elevated urine 11-dehydro-TXB2 in males with MS, including in some patients who are at a high or very high risk of ASCVDs. 11-dehydro-TXB2 levels are associated with hyperhomocysteinemia, inflammation, fat distribution, hypercholesterolemia, and adiponectin concentrations. Elevated 11-dehydro-TXB2 levels may support the use of personalised aspirin ASCVD prevention in high-risk males with MS. Giuseppe Patti.

References

Visseren F, Mach F, Smulders Y, Carballo D, Koskinas K, Back M . 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34):3227-3337. DOI: 10.1093/eurheartj/ehab484. View

Alberti K, Zimmet P, Shaw J . The metabolic syndrome--a new worldwide definition. Lancet. 2005; 366(9491):1059-62. DOI: 10.1016/S0140-6736(05)67402-8. View

Piazzolla G, Candigliota M, Fanelli M, Castrovilli A, Berardi E, Antonica G . Hyperhomocysteinemia is an independent risk factor of atherosclerosis in patients with metabolic syndrome. Diabetol Metab Syndr. 2019; 11:87. PMC: 6815401. DOI: 10.1186/s13098-019-0484-0. View

Selak V, Jackson R, Poppe K, Wu B, Harwood M, Grey C . Personalized Prediction of Cardiovascular Benefits and Bleeding Harms From Aspirin for Primary Prevention: A Benefit-Harm Analysis. Ann Intern Med. 2019; 171(8):529-539. DOI: 10.7326/M19-1132. View

Joseph P, Roshandel G, Gao P, Pais P, Lonn E, Xavier D . Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet. 2021; 398(10306):1133-1146. DOI: 10.1016/S0140-6736(21)01827-4. View

Takahashi S, Ushida M, Komine R, Shimizu A, Uchida T, Ishihara H . Increased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin. Thromb Res. 2006; 119(4):517-24. DOI: 10.1016/j.thromres.2006.04.004. View

Menzaghi C, Trischitta V . The Adiponectin Paradox for All-Cause and Cardiovascular Mortality. Diabetes. 2017; 67(1):12-22. PMC: 6181068. DOI: 10.2337/dbi17-0016. View

Lippi G, Danese E, Favaloro E . Harms and Benefits of Using Aspirin for Primary Prevention of Cardiovascular Disease: A Narrative Overview. Semin Thromb Hemost. 2018; 45(2):157-163. DOI: 10.1055/s-0038-1675380. View

Sanchez-Garcia S, Garcia-Pena C, Duque-Lopez M, Juarez-Cedillo T, Cortes-Nunez A, Reyes-Beaman S . Anthropometric measures and nutritional status in a healthy elderly population. BMC Public Health. 2007; 7:2. PMC: 1769489. DOI: 10.1186/1471-2458-7-2. View

10.

Tu W, Qiu H, Liu Y, Liu Q, Zeng X, Zhao J . Elevated levels of adiponectin associated with major adverse cardiovascular and cerebrovascular events and mortality risk in ischemic stroke. Cardiovasc Diabetol. 2020; 19(1):125. PMC: 7415178. DOI: 10.1186/s12933-020-01096-3. View

11.

Woodward L, Akoumianakis I, Antoniades C . Unravelling the adiponectin paradox: novel roles of adiponectin in the regulation of cardiovascular disease. Br J Pharmacol. 2016; 174(22):4007-4020. PMC: 5659989. DOI: 10.1111/bph.13619. View

12.

Cosentino F, Grant P, Aboyans V, Bailey C, Ceriello A, Delgado V . 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; 41(2):255-323. DOI: 10.1093/eurheartj/ehz486. View

13.

Carey R, Whelton P . The 2017 American College of Cardiology/American Heart Association Hypertension Guideline: A Resource for Practicing Clinicians. Ann Intern Med. 2018; 168(5):359-360. DOI: 10.7326/M18-0025. View

14.

Wang N, Vendrov K, Simmons B, Schuck R, Stouffer G, Lee C . Urinary 11-dehydro-thromboxane B2 levels are associated with vascular inflammation and prognosis in atherosclerotic cardiovascular disease. Prostaglandins Other Lipid Mediat. 2017; 134:24-31. PMC: 5803431. DOI: 10.1016/j.prostaglandins.2017.11.003. View

15.

Santilli F, Davi G, Patrono C . Homocysteine, methylenetetrahydrofolate reductase, folate status and atherothrombosis: A mechanistic and clinical perspective. Vascul Pharmacol. 2015; 78:1-9. DOI: 10.1016/j.vph.2015.06.009. View

16.

Davi G, Guagnano M, Ciabattoni G, Basili S, Falco A, Marinopiccoli M . Platelet activation in obese women: role of inflammation and oxidant stress. JAMA. 2002; 288(16):2008-14. DOI: 10.1001/jama.288.16.2008. View

17.

Roberts 2nd L, Sweetman B, OATES J . Metabolism of thromboxane B2 in man. Identification of twenty urinary metabolites. J Biol Chem. 1981; 256(16):8384-93. View

18.

Dasa O, Pepine C, Pearson T . Aspirin in Primary Prevention: What Changed? A Critical Appraisal of Current Evidence. Am J Cardiol. 2020; 141:38-48. DOI: 10.1016/j.amjcard.2020.11.014. View

19.

Santilli F, Vazzana N, Liani R, Guagnano M, Davi G . Platelet activation in obesity and metabolic syndrome. Obes Rev. 2011; 13(1):27-42. DOI: 10.1111/j.1467-789X.2011.00930.x. View

20.

Trovati M, Mularoni E, Burzacca S, Ponziani M, Massucco P, Mattiello L . Impaired insulin-induced platelet antiaggregating effect in obesity and in obese NIDDM patients. Diabetes. 1995; 44(11):1318-22. DOI: 10.2337/diab.44.11.1318. View